Caldesmon (CaD) is a major calmodulin- and actin-binding protein distributed in smooth muscle cells (SMC) and nonmuscle cells. There are at least two high-molecular-weight CaD (h-CaD) isoforms and four low-molecular-weight CaD (l-CaD) isoforms produced by alternative splicing. Isoformal interconversion is associated with phenotypic modulations of vascular SMC. We investigated the CaD isoform in human and rat glomerular mesangial cells (MC) to characterize the phenotypic changes of MC involved in glomerular diseases. A Western blot analysis and reverse-transcription analysis using exon-specific primers revealed that one l-CaD isoform lacking exons 1, 3b and 4 was predominantly expressed in human cultured MC. The expression of this isoform was markedly enhanced in anti-Thy1.1 nephritis rats and streptozotocin-induced diabetic rats, while little expression was observed in the normal glomerulus. Isoformal interconversion did not occur during the phenotypic changes of MC. These data suggested that the activated MC resembled dedifferentiated SMC in terms of the CaD expression pattern, and that CaD is a useful marker of the phenotypic modulations of MC.

1.
Schlondorff D: The glomerular mesangial cell: An expanding role for a specialized pericyte. FASEB J 1987;1:272–281.
2.
Kreisberg JL: Cell biology and biochemistry of the glomerular mesangium. Miner Electrol Metab 1988;14:167–175.
3.
Makino H, Hironaka K, Shikata K, Nagake Y, Kumagai I, Kashihara N, Ota Z: Mesangial matrices act as mesangial channels to juxtaglomerular zone: Tracer and high-resolution scanning electron microscopic study. Nephron 1994;66:181–188.
4.
Abrass CK, Peterson CV, Raugi G: Phenotypic expression of collagen types in mesangial matrix of diabetic and nondiabetic rats. Diabetes 1988;37:1695–1702.
5.
Okamoto K, Kashihara N, Sugiyama H, Sekikawa T, Maeshima Y, Kanao K, Satoh M, Maruyama K, Odawara M, Kasahara J, Sugaya T, Murakami K, Makino H: Suppression of phenotypic alteration of mesangial cells in diabetes induced in angiotensin II type 1a receptor deficient mice. J Am Soc Nephrol 1997;8:644A.
6.
Okamoto K, Kashihara N, Sugiyama H, Sekikawa T, Maeshima Y, Kanao K, Makino H, Ota Z: Characterization of caldesmon isoform in mesangial cell and analysis of expression mechanisms. J Am Soc Nephrol 1995;6:1026.
7.
Makino H, Kashihara N, Sugiyama H, Kanao K, Sekikawa T, Okamoto K, Maeshima Y, Ota Z, Nagai R: Phenotypic modulation of the mesangium reflected by contractile proteins in diabetes. Diabetes 1996;45:488–495.
8.
Makino H, Kashihara N, Sugiyama H, Kanao K, Sekikawa T, Shikata K, Nagai R, Ota Z: Phenotypic changes of the mesangium in diabetic nephropathy. J Diabetes Complications 1995;9:282–284.
9.
Johnson RJ: The glomerular response to injury: Progression or resolution? Kidney Int 1994;45:1769–1782.
10.
Alpers CE, Hudkins KL, Gown AM, Johnson RJ: Enhanced expression of ‘muscle-specific’ actin in glomerulonephritis. Kidney Int 1992;41:1134–1142.
11.
Johnson RJ, Floege J, Yoshimura A, Iida H, Couser WG, Alpers CE: The activated mesangial cells: A glomerular ‘myofibroblast’ ? J Am Soc Nephrol 1992;2:S190–S197.
12.
Drenckhahn D, Schnittler H, Noniling R, Kriz W: Ultrastructural organization of contractile proteins in rat glomerular mesangial cells. Am J Pathol 1990;137:1343–1351.
13.
Ishino T, Kobayashi R, Wakui H, Fukushima Y, Nakamoto Y, Miura AB: Biochemical characterization of contractile proteins of rat cultured mesangial cells. Kidney Int 1991;39:1118–1124.
14.
Elger M, Drenckhahn D, Nobiling R, Mundel P, Kruz W: Cultured rat mesangial cells contain smooth muscle α-actin not found in vivo. Am J Pathol 1993;1423:497–503.
15.
Makino H, Shikata K, Wieslander J, Wada J, Kashihara N, Yoshioka K, Ota Z: Localization of fibril/microfibril and basement membrane collagens in diabetic glomerulosclerosis in type 2 diabetes. Diabet Med 1994;11:304–311.
16.
Ueki N, Sobue K, Kanda K, Hada T, Higashino K: Expression of high and low molecular weight caldesmons during phenotypic modulation of smooth muscle cells. Proc Natl Acad Sci USA 1987;84:9049–9053.
17.
Glukhova MA, Kabakov AE, Frid MG, Ornatsky OI, Belkin AM, Mukhin DN, Orekhov AN, Koteliansky VE, Simirnov UN: Modulation of human aorta smooth muscle cell phenotype: A study of muscle-specific variants of vinculin, caldesmon, and actin expression. Proc Natl Acad Sci USA 1988;85:9542–9546.
18.
Novy RE, Lin JLC, Lin JJC: Characterization of cDNA clones encoding a human fibroblast caldesmon isoform and analysis of caldesmon expression in normal and transformed cells. J Biol Chem 1991;266:16917–16924.
19.
Yamashiro S, Yamakita Y, Yoshida K, Takiguchi K, Matsumura F: Characterization of COOH terminus of non-muscle caldesmon mutants lacking mitosis-specific phosphorylation sites. J Biol Chem 1995;270:4023–4030.
20.
Humphrey MB, Herrera-Sosa H, Gonzalez G, Lee R, Bryan J: Cloning of cDNAs encoding human caldesmons. Gene 1992;112:197–204.
21.
Hayashi K, Yano H, Hashida T, Takeuchi R, Takeda O, Asada K, Takahashi E, Kato I, Sobue K: Genomic structure of human caldesmon gene. Proc Natl Acad Sci USA 1992;89:12122–12126.
22.
Payne AM, Yue P, Pritchard K, Marston SB: Caldesmon mRNA splicing and isoform expression in mammalian smooth-muscle and non-muscle tissues. Biochem J 1995;305:445–450.
23.
Harper PA, Robinson JM, Hoover RL, Wright TC, Karnovsky MJ: Improved methods for culturing rat glomerular cells. Kidney Int 1984;26:875–880.
24.
Sugiyama H, Kashihara N, Makino H, Yamasaki Y, Ota Z: Reactive oxygen species induce apoptosis in cultured human mesangial cells. J Am Soc Nephrol 1996;7:2357–2363.
25.
Kreisberg J, Karnovsky MJ: Glomerular cells in culture. Kidney Int 1983;23:439–447.
26.
Kocher O, Skalli O, Cerutti D, Gabbiani G: Cytoskeletal features of rat aortic cells during development. An electron microscopic, immunohistochemical, and biochemical study. Circ Res 1985;56:829–838.
27.
Maeshima Y, Kashihara N, Yasuda T, Sugiyama H, Sekikawa T, Okamoto K, Kanao K, Watanabe Y, Kanwer YS, Makino H: Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo. J Clin Invest 1998;101:2589–2597.
28.
Sugiyama H, Kashihara N, Makino H, Yamasaki Y, Ota Z: Apoptosis in glomerular sclerosis. Kidney Int 1996;49:103–111.
29.
Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156–159.
30.
Onbe T, Kashihara N, Yamasaki Y, Makino H, Ota Z: Expression of mRNAs of cytokines and growth factors in experimental glomerulonephritis. Res Commun Mol Pathol Pharmacol 1994;86:131–138.
31.
Sekikawa T, Kashihara N, Maruyama K, Satoh M, Okamoto K, Kanao K, Maeshima Y, Sugiyama H, Yamasaki Y, Makino H: Expression of interleukin-8 in human glomerulonephritis. Res Commun Mol Pathol Pharmacol 1998;99:217–224.
32.
Maeshima Y, Kashihara N, Sugiyama H, Makino H, Ota Z: Antisense oligonucleotides to proliferating cell nuclear antigen and Ki-67 inhibit human mesangial cell proliferation. J Am Soc Nephrol 1996;7:2219–2229.
33.
Ando Y, Moriyama T, Miyazaki M, Akagi Y, Kawada N, Isaka Y, Izumi M, Yokoyama K, Yamauchi A, Horio M, Ando A, Ueda N, Sobue K, Imai E, Hori M: Enhanced glomerular expression of caldesmon in IgA nephropathy and its suppression by glucocorticoid-heparin therapy. Nephrol Dial Transplant 1998;13:1168–1175.
34.
Min B, Foster DN: The 5′-flanking region of the mouse vascular smooth muscle α-actin gene contains evolutionarily conserved sequence motifs within a functional promoter. J Biol Chem 1990;265:16667–16675.
35.
Shimizu RT, Blank RS, Jervis R, Lawrenz-Smith SC, Owens GK: The smooth muscle α-actin gene promoter is differentially regulated in smooth muscle versus non-smooth muscle cells. J Biol Chem 1995;270:7631–7643.
36.
Hautmann BB, Thompson MM, Swartz EA, Olson EN, Owens GK: Angiotensin II induced stimulation of smooth muscle alpha-actin expression by serum response factor and the homeodomain transcription factor Mhox. Circ Res 1997;81:600–610.
37.
Kitamura M, Kawachi H: Creation of an in vivo cytosensor using engineered mesangial cells. Automatic sensing of glomerular inflammation controls transgene activity. J Clin Invest 1997;100:1394–1399.
38.
Yano H, Hayashi K, Haruna M, Sobue K: Identification of two distinct promoters in the chicken caldesmon gene. Biochem Biophys Res Commun 1994;201:618–626.
39.
Yano H, Hayashi K, Momiyama T, Saga H, Haruna M, Sobue K: Transcriptional regulation of the chicken caldesmon gene. Activation of gizzard-type caldesmon promoter requires a CArG box-like motif. J Biol Chem 1995;270:23661–23666.
40.
Momiyama T, Hayashi K, Obata H, Nishida T, Ito T, Kamiike W, Matsuda H, Sobue K: Functional involvement of serum response factor in the transcriptional regulation of caldesmon gene. Biochem Biophys Res Commun 1998;242:429–435.
41.
Toutant M, Gauthier-Rouviere C, Fiszman MY, Lemonnier M: Promoter elements and transcriptional control of the chicken tropomyosin gene. Nucleic Acids Res 1994;22:1838–1845.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.